Loading clinical trials...
Loading clinical trials...
A Phase 1b Randomized, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
Conditions
Interventions
APL-1401
Placebo
Locations
4
United States
New Hope Research Development
Corona, California, United States
Guardian Angel Research Center
Tampa, Florida, United States
Tandem Clinical Research
Marrero, Louisiana, United States
Meridian Clinical Research
Rockville, Maryland, United States
Start Date
January 26, 2023
Primary Completion Date
March 1, 2025
Completion Date
April 1, 2025
Last Updated
September 6, 2023
NCT07271069
NCT04338204
NCT06975722
NCT07185009
NCT07184996
NCT07245394
Lead Sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions